Drug Profile
CER 522
Alternative Names: CER-522Latest Information Update: 11 Sep 2019
Price :
$50
*
At a glance
- Originator Cerenis Therapeutics; Montreal Heart Institute
- Developer Cerenis Therapeutics
- Class Peptides
- Mechanism of Action Apolipoprotein A I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Aortic valve stenosis